Due to positive effects in reducing cell proliferation by targeting the DUX4 fusion transcript by utilizing shRNA, it is possible that DUX-rearranged B-ALL may be prone to targeted therapy [228]. This evidence concerns the gene DUX4 and acute lymphoblastic leukemia.